Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;54(12):1944-1951.
doi: 10.1111/imj.16515. Epub 2024 Oct 23.

Pulmonary arterial hypertension: updates and perspective with newer therapies

Jyotika D Prasad  1   2 , Trevor J Williams  1 , Helen M Whitford  1
Affiliations
Review

Pulmonary arterial hypertension: updates and perspective with newer therapies

Jyotika D Prasad et al. Intern Med J. 2024 Dec.

Abstract

Pulmonary arterial hypertension (PAH) is a rare condition for which a remarkable change has been witnessed in the epidemiology, assessment and treatment landscape over the last three decades. Well-established registries from the Western world have not only highlighted the shift in the epidemiology to an older, more comorbid cohort but have also identified markers of prognosis that have been validated as part of risk stratification scores in multiple cohorts. The emphasis on early identification through a systematic assessment pathway and the option of upfront combination therapy with serial risk stratification assessment has laid the foundation for the standard of care and improved prognosis. This review provides an update on the assessment and newer therapies for PAH.

Keywords: pulmonary arterial hypertension; pulmonary hypertension; pulmonary vasodilators; treatment of pulmonary hypertension.

PubMed Disclaimer

References

    1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61: 61–144.
    1. Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 2019; 53: 1801887.
    1. Huertas A, Perros F, Tu L, Cohen‐Kaminsky S, Montani D, Dorfmüller P et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation 2014; 129: 1332–1340.
    1. Haji K, Wong CX, Chandra N, Truong H, Corkill W, Kaethner A et al. Pulmonary hypertension in Central Australia: a community‐based cohort study. Heart Lung Circ 2019; 28: 598–604.
    1. Naing P, Playford D, Strange G, Abeyaratne A, Berhane T, Joseph S et al. Top end pulmonary hypertension study: understanding epidemiology, therapeutic gaps and prognosis in remote Australian setting. Heart Lung Circ 2021; 30: 507–515.

MeSH terms

Substances

LinkOut - more resources